

Baxter

AIRWAY CLEARANCE THERAPIES



For Neuromuscular Patients



OUR PURPOSE IS CLEAR

For neuromuscular patients, inadequate airway clearance can lead to respiratory health issues.

WE'RE HERE TO HELP THESE PATIENTS BREATHE EASY.


With a full portfolio of airway clearance therapies, we may help your patients by reducing infections, hospitalizations, and improving their quality of life.¹

Airway clearance therapy may benefit patients with:

- Cerebral palsy (CP)
- Amyotrophic lateral sclerosis (ALS)
- Muscular dystrophy (MD)
- Spinal muscular atrophy (SMA)
- Spinal cord injuries (SCI)

The Vicious Cycle

If patients are unable to clear mucus from their lungs it accumulates, creating an environment where bacteria can grow, causing lung infections and further damage. This cycle can eventually lead to respiratory failure.



“ Respiratory failure is the most common cause of morbidity and mortality in patients with chronic or rapidly progressive neuromuscular disease.² ”

THE 3 ESSENTIALS FOR AIRWAY CLEARANCE




Effective airway clearance involves three essential processes: expansion of the lungs, mobilization of secretions, and evacuation of secretions.

Patients with neuromuscular conditions may need therapies for any or all of these processes.

EXPANSION

Continuous Positive Expiratory Pressure (CPEP) therapy expands the lungs to prevent or treat atelectasis, enabling mobilization and evacuation of secretions.





- 1,2 Continuous positive expiratory pressure and increased airflow combined with aerosol, opens the airways
- 3 Airflow during inspiration and expiration prevents or reverses atelectasis
- 4 Lung expansion allows air to move beyond retained secretions, aiding in mobilization



MOBILIZATION

Continuous High Frequency Oscillation (CHFO) therapy uses continuous pulses of positive pressure to loosen and mobilize secretions to the large airways.




- 1,2 Continuous pulses of positive pressure combined with aerosol, is delivered to the airways to loosen secretions
- 3 Continuous high frequency oscillation during both inspiration and expiration forms a pressure gradient
- 4 Accelerated expiratory airflow mobilizes secretions to the larger airways where they can be cleared by coughing or suctioning



EVACUATION

Mechanical Insufflation-Exsufflation (MIE) therapy simulates a cough to evacuate secretions.

- 1 Resting state
- 2 Patient's lungs are inflated with positive insufflation
- 3 Patient receives active negative exsufflation
- 4 PAP phase with "Resting Positive Pressure" setting maintains positive flow to the patient. Full cycle is repeated



THERAPIES TO FIT YOUR PATIENTS' NEEDS



VOLARA SYSTEM

EXPANSION	MOBILIZATION	EVACUATION
X	X	

The **Volara** System delivers, hospital-level Oscillation and Lung Expansion (OLE) therapy.¹

- 3-in-1 therapy combines CPEP, CHFO and nebulizer in one system
- Pre-set programs for your therapy protocols
- Use with tracheostomy, mask or mouthpiece
- Aerosol medication delivery

INDICATIONS

- Lung expansion therapy
- Mobilization of secretions
- Prevention and treatment of pulmonary atelectasis
- Supplemental oxygen delivery when used with oxygen supply



THE VEST APX SYSTEM

EXPANSION	MOBILIZATION	EVACUATION
	X	

The **Vest** APX System delivers High Frequency Chest Wall Oscillation (HFCWO).

- Available for use in the home
- Multiple programming options for flexible treatment
- Wrap and vest style garments available

INDICATIONS

- Mobilization of secretions when there is:
- Evidence or suggestion of retained secretions
 - Difficulty with secretion clearance



SYNCLARA COUGH SYSTEM

EXPANSION	MOBILIZATION	EVACUATION
		X

The **Synclara** Cough System simulates a cough, evacuating secretions that could otherwise collect in the upper airways.

- Home and acute care models available
- Use with mask, mouthpiece, or tracheostomy

INDICATIONS

- Secretion evacuation for patients who are unable to cough or clear secretions effectively from upper airways, due to reduced peak cough expiratory flow or respiratory muscle weakness

CARE CONNEX PROGRAM FOR SUPPORT

Baxter created the **CARE Connex** program to deliver comprehensive services at every step of the patient journey, offering new efficiencies for your practice and helping improve the therapy experience for your patients. We work with over a thousand leading local, regional and national companies to include commercial health plans and networks, Medicaid, Medicare, TRICARE and the Department of Veterans Affairs.

- Insurance provider services
- 24/7 clinical care with multilingual customer service and product support
- 600+ in-home licensed clinicians
- Continuing education courses
- Clinical in-home assessments, trainings, outcomes monitoring and reporting
- E-Prescribing available (Parachute, Epic, Cerner, Allscripts and others)

FOR FURTHER INFORMATION ABOUT PRODUCTS AND SERVICES

Please contact your Baxter sales representative or
call Baxter customer service at **1-800-426-4224**.

Rx Only. For safe and proper use of product mentioned herein, please refer to the Instructions for Use or Operator's Manual.

References

1. Huynh TT, Liesching TN, Cereda M, Lei Y, Frazer MJ, Nahouraii MR, et al. Efficacy of Oscillation and Lung Expansion in Reducing Postoperative Pulmonary Complication, *JACS* (2019)
2. Ambrosino N, Carpenè N, Gherardi M. Chronic Respiratory Care for Neuromuscular Diseases in Adults. *Eur Respir J*. 2009; 34: 444-451

Baxter.com

Baxter International Inc.
One Baxter Parkway / Deerfield, Illinois 60015

Hill-Rom reserves the right to make changes without notice in design, specifications and models. The only warranty Hill-Rom makes is the express written warranty extended on the sale or rental of its products.

Baxter, CARE Connex, Hillrom, Synclara, The Vest, and Volara are trademarks of Baxter International Inc. or its subsidiaries.

Any other trademarks, product names or brand images appearing herein are the property of their respective owners.

US-FLC189-220075 (v3.0) 01/2025